Everest Financial Group LLC Takes Position in Amgen Inc. $AMGN

Everest Financial Group LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,505 shares of the medical research company’s stock, valued at approximately $530,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. grew its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after buying an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC acquired a new position in Amgen during the 4th quarter worth $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen during the fourth quarter valued at about $22,441,000. Finally, Robinhood Asset Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $17,526,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AMGN shares. Weiss Ratings cut Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. Mizuho raised their target price on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. Morgan Stanley dropped their price target on Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. Guggenheim upped their price target on Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Finally, Truist Financial increased their price objective on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $356.62.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of AMGN opened at $376.04 on Monday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $202.95 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 3.80 and a beta of 0.41. The stock’s 50-day moving average price is $351.28 and its 200 day moving average price is $352.02.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts predict that Amgen Inc. will post 22.31 earnings per share for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.